qi.yang管理团队
这个人很懒，什么都没有留下～
23
文章
0
粉丝
-
【IND enabling】Once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety【Product for Licensing】
Project ID：DT-202500428-041 Product Brief Summary More highlights Contact us: For any ques…
-
【pre-PCC】A Potential Best-in-Class CDK2 Inhibitor with Better Selectivity, Better Efficacy and Superior PK【Product for Licensing】
Project ID：DT-202500410-038 Product Brief Summary More highlights Contact us: For any ques…
-
【Phase I】First-in-class Phase I Dual-target Oral Molecular Glue for Hematologic Malignancies with Broad-spectrum Activity and Better Safety Profile 【Product for Licensing】
Project ID：DT-202500410-037 Product Brief Summary More highlights Contact us: For any ques…
-
【Preclinical】A safer and more effective small-molecule regulator of miR-124 for IBD treatment 【Product for Licensing】
Project ID：BP-20240718-OR-77 Product Brief Summary More highlights Contact us…
-
High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb 【Product for Licensing】
Project ID：BP-20240318-OR-029 Product Brief Summary Key Advantages: It demonstrated potent…
-
A Highly Differentiated IL-2- Fc-IFN-α Fusion Protein for Cancer Combination Therapies 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
-
A FIC Her2xCD47xCD16a Tri-specific Antibody for Treating Her2 High and Low or Negative Cancers 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!
-
The Phase II Small Molecule targeting IL-17 & IL-4Ra solves unmet medical needs in Psoriasis and Atopic Dermatitis 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn
点击查看更多
